CN101300009B - 作为化学辐射敏化剂的喜树碱衍生物 - Google Patents

作为化学辐射敏化剂的喜树碱衍生物 Download PDF

Info

Publication number
CN101300009B
CN101300009B CN2006800390612A CN200680039061A CN101300009B CN 101300009 B CN101300009 B CN 101300009B CN 2006800390612 A CN2006800390612 A CN 2006800390612A CN 200680039061 A CN200680039061 A CN 200680039061A CN 101300009 B CN101300009 B CN 101300009B
Authority
CN
China
Prior art keywords
cpt
hydrogen
compound
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800390612A
Other languages
English (en)
Chinese (zh)
Other versions
CN101300009A (zh
Inventor
杨理希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dignity Health
Sutter Bay Hospitals
Original Assignee
Catholic Healthcare West
Sutter West Bay Hospitals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catholic Healthcare West, Sutter West Bay Hospitals filed Critical Catholic Healthcare West
Publication of CN101300009A publication Critical patent/CN101300009A/zh
Application granted granted Critical
Publication of CN101300009B publication Critical patent/CN101300009B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2006800390612A 2005-10-21 2006-10-19 作为化学辐射敏化剂的喜树碱衍生物 Expired - Fee Related CN101300009B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72892405P 2005-10-21 2005-10-21
US60/728,924 2005-10-21
US11/444,150 2006-05-30
US11/444,150 US7875602B2 (en) 2005-10-21 2006-05-30 Camptothecin derivatives as chemoradiosensitizing agents
PCT/US2006/041175 WO2007048002A2 (en) 2005-10-21 2006-10-19 Camptothecin derivatives as chemoradiosensitizing agents

Publications (2)

Publication Number Publication Date
CN101300009A CN101300009A (zh) 2008-11-05
CN101300009B true CN101300009B (zh) 2013-04-03

Family

ID=37963356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800390612A Expired - Fee Related CN101300009B (zh) 2005-10-21 2006-10-19 作为化学辐射敏化剂的喜树碱衍生物

Country Status (11)

Country Link
US (3) US7875602B2 (enExample)
EP (1) EP1951231B1 (enExample)
JP (1) JP5328357B2 (enExample)
KR (1) KR101320160B1 (enExample)
CN (1) CN101300009B (enExample)
AU (1) AU2006304811C1 (enExample)
CA (1) CA2626032C (enExample)
ES (1) ES2428088T3 (enExample)
NZ (2) NZ567454A (enExample)
TW (1) TWI402270B (enExample)
WO (1) WO2007048002A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101402640B (zh) * 2008-09-02 2011-06-15 暨南大学 双酯化喜树碱衍生物及其制备方法和应用
DE102009004204A1 (de) * 2009-01-09 2010-07-15 Christian-Albrechts-Universität Zu Kiel Verfahren zur verbesserten Bioaktivierung von Arzneistoffen
US8168648B2 (en) * 2009-03-06 2012-05-01 Taiwan Liposome Co., Ltd. Camptothecin derivatives and uses thereof
WO2010148138A2 (en) * 2009-06-17 2010-12-23 Threshold Pharmaceuticals, Inc. Camptothecin derivatives
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
TWI549679B (zh) * 2011-11-03 2016-09-21 台灣微脂體股份有限公司 疏水性喜樹鹼衍生物之醫藥組合物
US20140135357A1 (en) * 2012-11-12 2014-05-15 Taiwan Liposome Company, Ltd. Dose regime for camptothecin derivatives
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015098963A1 (ja) 2013-12-26 2015-07-02 東亞合成株式会社 カルレティキュリンの発現促進方法および該方法に用いられる合成ペプチド
JP6872713B2 (ja) 2015-05-29 2021-05-19 東亞合成株式会社 腫瘍細胞の放射線感受性を増大させる合成ペプチド及びその利用
CN112759603B (zh) * 2015-10-27 2022-09-09 加州太平洋医疗中心 鬼臼毒素衍生物及其应用
US10087194B2 (en) 2015-10-27 2018-10-02 California Pacific Medical Center Podophyllotoxin derivatives and their use
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2021005583A1 (en) 2019-07-11 2021-01-14 Sun Pharma Advanced Research Company Ltd. Camptothecin derivatives with a disulfide moiety and a piperazine moiety
WO2021154746A1 (en) 2020-01-28 2021-08-05 Reflexion Medical, Inc. Joint optimization of radionuclide and external beam radiotherapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403604B1 (en) * 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6423707B1 (en) * 2000-08-28 2002-07-23 California Pacific Medical Center Nitroimidazole ester analogues and therapeutic applications
US6855720B2 (en) * 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6933302B2 (en) * 2002-06-03 2005-08-23 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US554990A (en) * 1896-02-18 Target-throwing trap
US4399282A (en) 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5196413A (en) 1984-12-10 1993-03-23 Johnson Matthey, Inc. Platinum complexes and the like
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5175278A (en) 1985-06-28 1992-12-29 Merck & Co., Inc. Heteropolysaccharide S-657
US4727068A (en) 1985-10-23 1988-02-23 Johnson Matthey, Inc. Radiosensitization by cobalt and Fe(III) complexes
US5175287A (en) 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US5026694A (en) 1987-04-13 1991-06-25 The British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
US4921963A (en) 1987-04-13 1990-05-01 British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
US5304654A (en) 1987-06-10 1994-04-19 Yasunori Nishijima Fluorine-containing nitroimidazole compounds
CA1329206C (en) 1987-06-10 1994-05-03 Tsutomu Kagiya Fluorine-containing nitroazole derivatives and radiosensitizer comprising the same
US4797397A (en) 1987-07-31 1989-01-10 Warner-Lambert Company 2-nitroimidazole derivatives useful as radiosensitizers for hypoxic tumor cells
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
JPH0819111B2 (ja) 1987-10-22 1996-02-28 ポーラ化成工業株式会社 ２―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤
US5036096A (en) 1988-11-25 1991-07-30 Warner-Lambert Company Aziridino derivatives of nitroimidazoles and pharmaceutical compositions of selected derivatives
US4954515A (en) 1988-11-25 1990-09-04 Warner-Lambert Company Haloalkylaminomethyl-2-nitro-1H-imidazoles
IL92597A0 (en) 1988-12-14 1990-08-31 Yasunori Nishijima President K Novel fluorine-containing 2-nitroimidazole derivatives and radiosensitizer comprising the same
US5043165A (en) 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US5077057A (en) 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5294715A (en) 1991-02-01 1994-03-15 University Of Pittsburgh Acridine-intercalator based hypoxia selective cytotoxins
CA2097163C (en) 1992-06-01 2002-07-30 Marianna Foldvari Topical patch for liposomal drug delivery system
MX9304399A (es) 1992-07-31 1994-02-28 Warner Lambert Co Proceso novedoso para preparar [[2-bromoetil)-amino]metil]-2-nitro-1h-imidazol-1-etanol quiral y compuestos relacionados.
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5646159A (en) 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
GB9504065D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Poly-pyrrolecarboxamidonaphthalenic acid derivatives
US5736156A (en) 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
US6060604A (en) 1995-03-31 2000-05-09 Florida State University Pharmaceutical compounds comprising polyamines substituted with electron-affinic groups
JPH08333370A (ja) 1995-06-08 1996-12-17 Kyorin Pharmaceut Co Ltd 水に可溶な新規フルオロエチルカンプトテシン誘導体、及びその製造方法
GB9512670D0 (en) 1995-06-21 1995-08-23 Sod Conseils Rech Applic Camptothecin analogues
US6339091B1 (en) 1995-06-21 2002-01-15 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Comptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues
CN1211919A (zh) 1995-09-13 1999-03-24 佛罗里达州立大学 放射增敏性紫杉烷及其药物制剂
WO1997019085A1 (en) 1995-11-22 1997-05-29 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
US6096336A (en) 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US5731316A (en) 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US5874105A (en) 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
CA2262745C (en) 1996-08-19 2006-04-04 Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives
EP0927025A4 (en) 1996-09-18 2001-07-25 Dragoco Inc DRY POWDER COMPOSITION WITH ACTIVE INGREDIENT ENCLOSED IN LIPOSOMES
CA2264227A1 (en) 1996-09-27 1998-04-02 Raymond A. Firestone Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998014459A1 (de) 1996-09-30 1998-04-09 Bayer Aktiengesellschaft Glycokonjugate von modifizierten camptothecin-derivaten (20-o-verknüpfung)
KR100219562B1 (ko) * 1996-10-28 1999-09-01 윤종용 반도체장치의 다층 배선 형성방법
SG104284A1 (en) 1996-10-30 2004-06-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
WO1998035940A1 (en) 1997-02-14 1998-08-20 Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives
JP3209509B2 (ja) * 1997-03-28 2001-09-17 インターナショナル・ビジネス・マシーンズ・コーポレーション ディスク状記録装置及びディスクドライブ装置
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
GB9721070D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
US5935949A (en) 1998-03-20 1999-08-10 Trustees Of Dartmouth College Use of androgen therapy in fibromyalgia and chronic fatigue syndrome
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6057303A (en) 1998-10-20 2000-05-02 Bionumerik Pharmaceuticals, Inc. Highly lipophilic Camptothecin derivatives
US6207832B1 (en) 1999-04-09 2001-03-27 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
US6281223B1 (en) 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
AU4822500A (en) 1999-05-04 2000-11-17 Bionumerik Pharmaceuticals, Inc. Novel highly lipophilic camptothecin analogs
US6765019B1 (en) 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
US6228855B1 (en) * 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
CA2391534A1 (en) * 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
GB0119578D0 (en) 2001-08-10 2001-10-03 Pharmacia & Upjohn Spa Fluoro linkers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423707B1 (en) * 2000-08-28 2002-07-23 California Pacific Medical Center Nitroimidazole ester analogues and therapeutic applications
US6403604B1 (en) * 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6855720B2 (en) * 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6933302B2 (en) * 2002-06-03 2005-08-23 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives

Also Published As

Publication number Publication date
KR101320160B1 (ko) 2013-10-23
US20080318873A1 (en) 2008-12-25
WO2007048002A2 (en) 2007-04-26
JP5328357B2 (ja) 2013-10-30
EP1951231B1 (en) 2013-07-31
NZ567454A (en) 2011-07-29
KR20080086436A (ko) 2008-09-25
WO2007048002A3 (en) 2007-09-13
US8779138B2 (en) 2014-07-15
TW200730532A (en) 2007-08-16
US20110184009A1 (en) 2011-07-28
ES2428088T3 (es) 2013-11-05
TWI402270B (zh) 2013-07-21
AU2006304811C1 (en) 2012-11-01
AU2006304811A1 (en) 2007-04-26
NZ593706A (en) 2012-11-30
HK1115321A1 (en) 2008-11-28
EP1951231A2 (en) 2008-08-06
CA2626032C (en) 2011-12-06
US20070093432A1 (en) 2007-04-26
AU2006304811B2 (en) 2012-03-22
CN101300009A (zh) 2008-11-05
JP2009512714A (ja) 2009-03-26
US7875602B2 (en) 2011-01-25
US8563537B2 (en) 2013-10-22
CA2626032A1 (en) 2007-04-26
EP1951231A4 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
CN101300009B (zh) 作为化学辐射敏化剂的喜树碱衍生物
JP6008864B2 (ja) モルホリニルアントラサイクリン誘導体の調製方法
CN100406013C (zh) 喜树碱衍生物
JP2001501596A (ja) バイオコンジュゲートおよび生物学的活性剤の送達
EP2717699B1 (en) Acid-labile lipophilic prodrugs of chemo-therapeutic anti-cancer agents
CN1901901B (zh) 紫杉醇-脂肪酸结合物及其药物组合物
CN101328159B (zh) 紫杉烷前体抗癌药及其药物组合物和用途
CN104327097A (zh) 雷帕霉素的三氮唑衍生物和用途
US9655975B2 (en) Prodrug using nitroimidazole
HK1115321B (en) Camptothecin derivatives as chemoradiosensitizing agents
EP3560914A1 (en) Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof
JP2004292426A (ja) 抗菌剤と抗ガン剤
CN101402640B (zh) 双酯化喜树碱衍生物及其制备方法和应用
CN110981888B (zh) N-芳基二硫吡咯酮脲类和氨基酯类衍生物及其制备和应用
US9321781B2 (en) Topoisomerase inhibitors
EP1758904B1 (en) Flavopereirine derivatives for cancer therapy
CN112494650A (zh) 一种血卟啉衍生物联合化学药物在肝癌治疗中的应用
Wu et al. Synthesis, Biological Evaluation and Mechanistic Insights of Natural-Product-Inspired Rubrolide Analogues as Antitumor Agents
CN112516313A (zh) 一种血卟啉衍生物联合化学药物在结肠癌治疗中的应用
WO2025247302A1 (zh) 一种喜树碱类化合物及其应用
HK1196556A (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: California, USA

Applicant after: SUTTER WEST BAY HOSPITALS

Co-applicant after: Western Catholic Church Health Organization (also operating in the name of St. Mary's Medical Center)

Address before: California, USA

Applicant before: CALIFORNIA PACIFIC MEDICAL CENTER

Co-applicant before: Western Catholic Church Health Organization (also operating in the name of St. Mary's Medical Center)

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: CALIFORNIA PACIFIC MED CENTER TO: SHATE XIWAN HOSPITAL

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: California, USA

Patentee after: SUTTER WEST BAY HOSPITALS

Patentee after: Dignity Health Centre

Address before: California, USA

Patentee before: Sutter West Bay Hospitals

Patentee before: Western Catholic Church Health Organization (also operating in the name of St. Mary's Medical Center)

EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20081105

Assignee: TLC BIOPHARMACEUTICALS, Inc.

Assignor: SUTTER WEST BAY HOSPITALS|Dignity Health Centre

Contract record no.: 2016990000194

Denomination of invention: Camptothecin derivatives as chemoradiosensitizing agents

Granted publication date: 20130403

License type: Exclusive License

Record date: 20160510

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: California, USA

Patentee after: Sutter Bay Hospital

Patentee after: Dignity Health Centre

Address before: California, USA

Patentee before: Sutter West Bay Hospitals

Patentee before: Dignity Health Centre

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130403